Cited by 122Neuroinflammation and Neurodegeneration MechanismsInflammasome and immune disordersParkinson's Disease Mechanisms and Treatments

Microglial NLRP3 Inflammasome Activation Upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies

Open access
Scheiblich, Hannah, Bousset, Luc, Schwartz, Stephanie, Griep, Angelika, Latz, Eicke, Melki, Ronald, Heneka, Michael T·2021·The Journal of Immunology

Abstract

Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder and is characterized by the formation of cellular inclusions inside neurons that are rich in an abnormal form of the protein α-synuclein (α-syn). Microglia are the CNS resident immune cells that react to misfolded proteins through pattern recognition receptor ligation and activation of signaling transduction pathways. Here, we studied activation of primary microglia isolated from wild-type mouse by distinct α-syn forms and their clearance. Internalization of α-syn monomers and oligomers efficiently activated the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome via TLR2 and TLR5 ligation, thereby acting on different signaling checkpoints. We found that primary microglia effectively engulf α-syn but hesitate in its degradation. NLRP3 inhibition by the selective inhibitor CRID3 sodium salt and NLRP3 deficiency improved the overall clearance of α-syn oligomers. Together, these data show that distinct α-syn forms exert different microglial NLRP3 inflammasome activation properties, thereby compromising its degradation, which can be prevented by NLRP3 inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.2100035

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alpha-synuclein binding to TLR2 and TLR5 induces microglial NLRP3 inflammasome activation, which is a shared signature seen in LDAM.

    “alpha-synuclein binding to TLR2 and TLR5 induces microglial NLRP3 inflammasome activation, which is a shared signature seen in LDAM36.”

    From APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia (2024) · cites this paper as [36]

    The Discussion (page not available) reports that α-synuclein monomers and oligomers act through TLR2 to prime the microglial NLRP3 inflammasome and through TLR5 to activate it. The paper does not identify this activation as a shared signature of LDAM; searches for LDAM and lipid-droplet-associated microglia found no supporting passage. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 59 · Cited by 122

Authors
Scheiblich, H., Bousset, L., Schwartz, S., Griep, A., Latz, E., Melki, R., & Heneka, M. T.
Affiliations
  • University of Bonn (DE)
  • Centre National de la Recherche Scientifique (FR)
  • German Center for Neurodegenerative Diseases (DE)
Corresponding author
Heneka, Michael T
Venue
The Journal of Immunology
Published
2021-10
Volume
207
Issue
8
Pages
2143-2154
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W3198590465
Cited by
122
References
59
Citations by year
2026: 22 · 2025: 21 · 2024: 30 · 2023: 24 · 2022: 20 · 2021: 4
FWCI
4.65
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • SSRN Electronic Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • DZNE Pub (submittedVersion)
Funders
  • EU Joint Programme - Neurodegenerative Disease Research (JPND-SYNACTION-ANR-15-JPWG-0012-03, TransPath-ND-ANR-17-JPCD-0002-02)
  • Gemeinnützige Hertie-Stiftung
  • Deutsche Forschungsgemeinschaft (EXC2151 - 390873048)
  • Centre National de la Recherche Scientifique
  • Fondation pour la Recherche Médicale (DEQ. 20160334896)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
NLRP3 inflammasome, microglia, alpha-synuclein, Parkinson's disease, TLR2, TLR5, alpha-synuclein oligomers, protein clearance, pattern recognition receptors, neuroinflammation, protein internalization
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Microglia, Toll-Like Receptor 2, Toll-Like Receptor 5, Mice, alpha-Synuclein, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review